Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orchard Therapeutics plc - American Depositary Shares (NQ:ORTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Orchard Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 Next >
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics: Q3 Earnings Insights
 
Via Benzinga
Why Orchard Therapeutics Stock Is Soaring Today
A buyout offer is fueling a rise in the company's shares today. 
Via The Motley Fool
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of... 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
From Kahn Swick & Foti, LLC
Via Business Wire
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
New clinical data beyond previously reported neurological and skeletal results demonstrate favorable outcomes for multiple disease manifestations not effectively addressed by the current standard of... 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Sarepta Therapeutics Stock Showing Rising Relative Strength
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
From Kahn Swick & Foti, LLC
Via Business Wire
Crude Oil Down 2%; ConAgra Brands Earnings Top Views
U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 40 points on Thursday. The Dow traded down 0.12% to 33,088.44 while the NASDAQ fell 0.23% to... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent... 
Via Benzinga
Dow Tumbles Over 100 Points; Constellation Brands Raises Profit Forecast
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.45% to 32,980.31 while the NASDAQ fell 0.62% to 13,154.24. The... 
Via Benzinga
Topics Stocks
Highly Rated Biotech Orchard Therapeutics Scores A Takeover, Shares Nearly Double
The company is working on stem cell-based gene therapies for severe rare diseases. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SP® Plus Corporation (Nasdaq - SP), Orchard Therapeutics plc (Nasdaq - ORTX), Summit Materials (NYSE - SUM)
From Brodsky & Smith LLC
Via GlobeNewswire
Lamb Weston, SP Plus And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Dow Falls 50 Points; Weekly Jobless Claims Edge Higher
U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Thursday, the Dow traded down 0.15% to 33,078.88 while the NASDAQ fell 0.28% to 13,199.32.... 
Via Benzinga
Topics Stocks
Orchard Therapeutics PLC (NASDAQ: ORTX) Sets New 52-Week High in Thursday Session
Via Investor Brand Network
ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Why Is Cambium Networks (CMBM) Stock Down 35% Today?
Cambium Networks isn't doing so hot on Thursday with shares of CMBM stock falling alongside preliminary earnings results for Q3! 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback